InSpectrum for IBD
Research type
Research Study
Full title
InSpectrum: Reducing disparities in IBD care in the post-COVID-19 era
IRAS ID
295098
Contact name
Simon Travis
Contact email
Sponsor organisation
University of Oxford/Clinical Trials and Research Governance
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Inflammatory bowel disease (IBD) is a collective term to described two main conditions: ulcerative colitis (UC) and Crohn's disease (CD). Both are lifelong conditions with no known cause. IBD follows an unpredictable course with intermittent periods of relapse and potentially severe symptom onset, significantly impacting on the patient's quality of life (QoL) and causing high lifetime costs associated with a patient's care.
InSpectrum is designed to create a system for analysing the mass patient-reported data collected by patients through a secure software platform called TrueColours-IBD, a digital monitoring platform developed in Oxford and in daily use for the clinical care of patients with UC or CD. The goal is to harness this data from TrueColours to develop InSpectrum, a multi-dimensional analytical tool for patient-entered data to act as an intelligent decision-support system that will enhance clinical management of patients with UC or CD.
REC name
South Central - Oxford A Research Ethics Committee
REC reference
21/SC/0357
Date of REC Opinion
4 Nov 2021
REC opinion
Favourable Opinion